Literature DB >> 27521563

Improvement in achievement of lipid targets in France: Comparison of data from coronary patients in the DYSIS and DYSIS II studies.

Jean Ferrières1, Maja Velkovski Rouyer2, Dominik Lautsch2, Baishali M Ambegaonkar2, Martin Horack3, Philippe Brudi2, Anselm K Gitt4.   

Abstract

Entities:  

Keywords:  Coronary heart disease; Ezetimibe; Hyperlipidaemia; LDL-cholesterol; Target

Mesh：

Substances：

Year:  2016        PMID： 27521563     DOI： 10.1016/j.ijcard.2016.08.084

Source DB:  PubMed          Journal:  Int J Cardiol        ISSN： 0167-5273            Impact factor:   4.164


× No keyword cloud information.
  4 in total

1.  Lipid Lowering Treatment and Eligibility for PCSK9 Inhibition in Post-Myocardial Infarction Patients in Italy: Insights from Two Contemporary Nationwide Registries.

Authors:  Furio Colivicchi; Michele Massimo Gulizia; Marcello Arca; Pier Luigi Temporelli; Lucio Gonzini; Vanessa Venturelli; Nuccia Morici; Ciro Indolfi; Domenico Gabrielli; Leonardo De Luca
Journal:  Cardiovasc Ther       Date:  2020-01-03       Impact factor: 3.023

2.  Achievement of Low-Density Lipoprotein Cholesterol Targets in CKD.

Authors:  Ziad A Massy; Jean Ferrières; Eric Bruckert; Céline Lange; Sophie Liabeuf; Maja Velkovski-Rouyer; Bénédicte Stengel
Journal:  Kidney Int Rep       Date:  2019-07-30

3.  Control of Low-Density Lipoprotein Cholesterol in Secondary Prevention of Coronary Artery Disease in Real-Life Practice: The DAUSSET Study in French Cardiologists.

Authors:  Jean Ferrières; François Roubille; Michel Farnier; Patrick Jourdain; Denis Angoulvant; Franck Boccara; Nicolas Danchin
Journal:  J Clin Med       Date:  2021-12-17       Impact factor: 4.241

Review 4.  Role of Lipid-Lowering Therapy in Low-Density Lipoprotein Cholesterol Goal Attainment: Focus on Patients With Acute Coronary Syndrome.

Authors:  Qinqin Wang; Chun Liang
Journal:  J Cardiovasc Pharmacol       Date:  2020-12       Impact factor: 3.271
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.